Oncolytic virotherapy for head and neck cancer: current research and future developments.

about

Infection: a Cause of and Cure for Cancer.

P2860

Q47142729-4F0D86C8-461B-4140-95E7-0A42F8DA920E

P2860

Oncolytic virotherapy for head and neck cancer: current research and future developments.

Item

http://www.wikidata.org/entity/Q38924562

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Oncolytic virotherapy for head and neck cancer: current research and future developments.

@en

type

Item

label

Oncolytic virotherapy for head and neck cancer: current research and future developments.

@en

prefLabel

Oncolytic virotherapy for head and neck cancer: current research and future developments.

@en

P1476

Oncolytic virotherapy for head and neck cancer: current research and future developments.

@en

P2093

Akshiv Malhotra

http://www.w3.org/2001/XMLSchema#string

Arun Sendilnathan

http://www.w3.org/2001/XMLSchema#string

Matthew O Old

http://www.w3.org/2001/XMLSchema#string

Trisha M Wise-Draper

http://www.w3.org/2001/XMLSchema#string

P2860

Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers

Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors

Differential sensitivity of normal and transformed human cells to reovirus infection

Herpes simplex virus type 1 mediates fusion through a hemifusion intermediate by sequential activity of glycoproteins D, H, L, and B

ras oncogenes in human cancer: a review

High interstitial fluid pressure - an obstacle in cancer therapy

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

Anti-tumor effect of oncolytic herpes simplex virus G47delta on human nasopharyngeal carcinoma.

Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model

Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer.

P304

83-93

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OV.S54503

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-07-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27512673

http://www.w3.org/2001/XMLSchema#string

P921

oncolytic virus

P932

4918384

http://www.w3.org/2001/XMLSchema#string

Oncolytic virotherapy for head and neck cancer: current research and future developments.

about

P2860

P2860

Oncolytic virotherapy for head and neck cancer: current research and future developments.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P921

P932